The primary treatment for hepatitis B is currently antiviral therapy. There are two main types of antiviral therapy: interferon injections and nucleoside oral medications. So is it better to use interferon or nucleoside oral drugs? First of all, let’s analyze the characteristics of interferon and nucleoside analogues. Interferon: The anti-hepatitis B virus efficacy of interferon is achieved through its direct antiviral effect and immunomodulatory effect. On the one hand, it regulates and enhances the body’s immune response and activates the antiviral lymphokines; on the other hand, it can also directly inhibit the hepatitis B virus. Because it can both directly inhibit hepatitis B virus and indirectly inhibit hepatitis B virus through the body’s immune response, once interferon treatment is effective its efficacy is relatively stable and not easy to relapse. The course of interferon treatment is one year, and the drug can be discontinued upon completion of the course of treatment. However, there can be fever, bone marrow suppression and other adverse reactions during interferon treatment. Nucleoside analogues: including lamivudine, adefovir, entecavir, and telbivudine. Nucleoside analogs can rapidly suppress the hepatitis B virus, but they cannot completely eliminate the hepatitis B virus. Therefore, the hepatitis B virus turns negative during treatment with nucleoside analogs, and once the drugs are discontinued, it is easy to relapse again. It is important to adhere to the treatment for many years before considering stopping the drug. In summary, the advantages of interferon: the course of treatment is definite, and the drug can be stopped one year after treatment. Disadvantages: there are many adverse effects. Advantages of nucleoside analogues: rapid suppression of hepatitis B virus with few adverse effects. Disadvantages: the course of treatment is uncertain, and often the drug cannot be stopped after several years of use. In the antiviral treatment of chronic hepatitis B we can choose the medication according to the different characteristics of the two drugs. 1, for the general chronic hepatitis B, compensated hepatitis B cirrhosis choose interferon or choose nucleoside analogues are correct. The only thing is that interferon can end the treatment in one year, while nucleoside analogs need to use more years of drugs, but with interferon may have some side effects, while nucleoside analogs rarely side effects. 2, young people, couples who have not yet had children: interferon should be preferred. Because interferon treatment can be stopped in a year. Most of them will not relapse after stopping the medication. Half a year after stopping the drug will be able to have children. 3, with hyperthyroidism, diabetes, depression, leukopenia of chronic hepatitis B patients: should be selected nucleoside analogues. Because these patients are not suitable for treatment with interferon, there is a risk of aggravating these diseases. 4, decompensated hepatitis B cirrhosis available nucleoside analogues, interferon is prohibited, because it may lead to loss of liver function and worsen the condition.